- In March 2024, GlaxoSmithKline plc expanded its popular Biotène product line with a new alcohol-free, long-lasting gel formulation, specifically targeting patients undergoing cancer treatments and those with chronic dry mouth. This development reflects the company’s commitment to advancing patient care through innovative, gentle, and effective xerostomia management solutions tailored to sensitive users. The launch also emphasizes the growing demand for preservative-free and biocompatible saliva substitutes in clinical and at-home settings
- In February 2024, ICPA Health Products Ltd. introduced Xerodent Pro, a dissolving tablet-based artificial saliva product in India. Developed to offer convenient and portable relief for patients on-the-go, Xerodent Pro is enriched with enzymes and xylitol to support oral health while alleviating dry mouth symptoms. This move highlights ICPA’s focus on product diversification and increasing accessibility to specialized oral care in emerging markets
- In January 2024, Sunstar Suisse S.A. launched a new oral spray variant under its GUM Hydral line, targeting global markets with a preservative-free and pH-balanced formulation. Designed for quick relief and ease of use, the product supports increased comfort for users with radiation-induced xerostomia. The initiative strengthens Sunstar’s position in the preventive and supportive oral care segment
- In November 2023, Cambridge Healthcare Supplies Ltd. announced a strategic collaboration with NHS England to supply its artificial saliva products across public healthcare institutions, ensuring affordable and consistent access for patients dealing with chronic dry mouth. This partnership emphasizes the growing role of public-private cooperation in expanding supportive care services
- In September 2023, Oral Science International Inc. completed clinical trials for its new mucoadhesive saliva substitute gel, formulated with advanced polymer technology for prolonged retention in the oral cavity. The gel showed superior hydration performance and patient satisfaction in comparison to conventional products, marking a significant step forward in xerostomia care. This reflects the industry’s trend toward innovation backed by clinical validation
